In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas 1

Histone modification has emerged as a promising approach to cancer therapy. We explored the in vivo efficacy of a butyric acid derivative, pivaloyloxymethyl butyrate (AN-9), for the treatment of gliomas. Relative to control and single-modality treatments, the combination of AN-9 and radiation significantly inhibited tumor growth and prolonged time to failure in mice bearing glioma xenografts. The enhanced response to radiation was accompanied by inhibition of cellular proliferation and by increased phosphorylation of H2AX, implicating DNA double-strand breaks in the antineoplastic effects of AN-9 and radiation. The data suggest that AN-9 in combination with radiation may be an effective therapy for malignant gliomas.

[1]  K. Aldape,et al.  Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms , 2006, Clinical Cancer Research.

[2]  A. Nudelman,et al.  The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs , 2006, Investigational New Drugs.

[3]  R. Stupp,et al.  New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy. , 2006, Neurosurgical focus.

[4]  S. Vandenberg,et al.  Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas , 2005, Molecular Cancer Therapeutics.

[5]  Z. Malik,et al.  In vivo and in vitro antitumor activity of butyroyloxymethyl‐diethyl phosphate (AN‐7), a histone deacetylase inhibitor, in human prostate cancer , 2005, International journal of cancer.

[6]  S. Tucker,et al.  Histone Deacetylase Inhibitors Radiosensitize Human Melanoma Cells by Suppressing DNA Repair Activity , 2005, Clinical Cancer Research.

[7]  R. Blaheta,et al.  Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studies , 2005, Medicinal research reviews.

[8]  K. Camphausen,et al.  Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid , 2005, International journal of cancer.

[9]  H. Keer,et al.  Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. , 2004, Lung cancer.

[10]  M. E. Robinson,et al.  Favorable Neuroblastoma Genes and Molecular Therapeutics of Neuroblastoma , 2004, Clinical Cancer Research.

[11]  P. Olive,et al.  Phosphorylation of histone H2AX as a measure of radiosensitivity. , 2004, International journal of radiation oncology, biology, physics.

[12]  A. Wozniak,et al.  Chronic Oral Administration of CI-994: A Phase I Study , 2004, Investigational New Drugs.

[13]  C. Britten,et al.  A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  S. Vandenberg,et al.  Protein kinase C-eta regulates resistance to UV- and gamma-irradiation-induced apoptosis in glioblastoma cells by preventing caspase-9 activation. , 2002, Neuro-oncology.

[15]  A. Nudelman,et al.  Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). , 2001, Cancer research.

[16]  R A Rifkind,et al.  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. , 2000, Cancer research.

[17]  T. Tsuruo,et al.  A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Nudelman,et al.  Novel anticancer prodrugs of butyric acid. 2. , 1992, Journal of medicinal chemistry.